Abstracts tagged "remission and vasculitis"

Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…
Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].